APPENDIX A-2

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

Health Technology Appraisal

Docetaxel for the treatment of hormone-refractory metastatic prostate cancer

Provisional matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Manufacturers/sponsors • Aventis Pharma Ltd Patient/carer groups • CancerBACUP • Cancer Voices • Long-term Medical Conditions Alliance • Macmillan Cancer Relief • Marie Curie Cancer Care • National Cancer Alliance • National Council for Hospice and Specialist Palliative Care Services • Prostate Cancer Charity • Prostate Cancer Support Association • Prostate Help Association • Tenovus Cancer Information Centre Professional groups • British Geriatrics Society • British Oncological Association • British Oncology Pharmacy Association (BOPA) • British Prostate Group • British Psychosocial Oncology Society (BPOS) • Cancer Research UK • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians' Medical Oncology Joint Special Committee • Royal College of Surgeons	General • Board of Community Health Councils in Wales • British National Formulary • National Collaborating Centre for Acute Care • National Public Health Service for Wales • NHS Confederation • NHS Purchasing and Supplies Agency • NHS Quality Improvement Scotland Comparator manufacturers • Mayne Pharma plc • Wyeth Pharmaceuticals (Lederle) • Baxter Healthcare Ltd • Pfizer Ltd Relevant research groups • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute Assessment team • National Coordinating Centre for Health Technology Assessment • NHS Centre for Reviews & Dissemination –York

• Royal Pharmaceutical Society Others • Department of Health • Greenwich PCT • Erewash PCT • Welsh Assembly Government	

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government; relevant NHS organisations in England and local health boards in Wales.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and consultee organisations representing patient/carers and professionals can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, the *British National Formulary*, and the British Medical Association.

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).